2023 ACR/EULAR antiphospholipid syndrome classification criteria - Université de Montpellier
Article Dans Une Revue Annals of the Rheumatic Diseases Année : 2023

2023 ACR/EULAR antiphospholipid syndrome classification criteria

1 Weill Cornell Medicine [Cornell University]
2 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
3 Faculty of Medical and Health Sciences [Auckland]
4 Middlemore Hospital
5 Pôle S2R - Service d'Epidémiologie et Evaluations Cliniques [CHRU Nancy]
6 CHU Pitié-Salpêtrière [AP-HP]
7 USP - Universidade de São Paulo = University of São Paulo
8 Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia [Brescia]
9 Istanbul University
10 Hokkaido University Hospital [Sapporo]
11 University of Ljubljana
12 NYU - New York University [New York]
13 KCH - King's College Hospital
14 School of Medicine [University of Utah, Salt Lake City]
15 Centro Hospitalar do Porto
16 HUG - Hôpitaux universitaires de Genève = University Hospitals of Geneva
17 UAB - Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona
18 UCLH - University College London Hospitals
19 Hôpital Cochin [AP-HP]
20 McMaster University [Hamilton, Ontario]
21 UNIRIO - Universidade Federal do Estado do Rio de Janeiro
22 OHRI - Ottawa Hospital Research Institute [Ottawa]
23 UC Irvine - University of California [Irvine]
24 Ghent University Hospital
25 Mayo Clinic [Rochester]
26 CHU Tenon [AP-HP]
27 University of Washington [Seattle]
28 IDESP - Institut Desbrest de santé publique
29 Addenbrooke's Hospital
30 Massachusetts General Hospital [Boston]
31 Northwell Health
32 University of Michigan [Ann Arbor]
33 University of Toronto
34 YSM - Yale School of Medicine [New Haven, Connecticut]
35 Department of Medicine, Division of Rheumatology, Kings County Hospital Center, New York Health and Hospitals, Brooklyn, NY, USA
36 Maimonides Medical Center
37 GlaxoSmithKline
38 UMCU - University Medical Center [Utrecht]
39 TU Graz - Technische Universität Graz
40 UJ - Uniwersytet Jagielloński w Krakowie = Jagiellonian University
41 IAI - Istituto Auxologico Italiano IRCCS Ospedale San Luca [Milan, Italy]
42 UNIVR - Università degli studi di Verona = University of Verona
43 Duke University Medical Center
44 AOUP - Azienda Ospedale Università di Padova = Hospital-University of Padua
45 Johns Hopkins University School of Medicine [Baltimore]
46 GO-Crear - Centro Regional de Enfermedades Autoinmunes y Reumáticas de Grupo Oroño
47 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
48 CIC Hôpital Bichat
49 UNC - University of North Carolina [Chapel Hill]
50 Guy's and St Thomas' NHS Foundation Trust
51 UNITO - Università degli studi di Torino = University of Turin
52 NKUA - National and Kapodistrian University of Athens
53 University of Texas Medical Branch at Galveston
54 RID-AGE - Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167
55 Service d'Obstétrique et de Gynécologie [CHRU Nancy]
56 Brigham and Women's Hospital [Boston]
Mary-Carmen Amigo
  • Fonction : Auteur
Michael Belmont
Nathalie Costedoat-Chalumeau
Ali Duarte-García
Nina Kello
Jason Knight
Karen Costenbader
Doruk Erkan

Résumé

Objective. To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods This international multidisciplinary initiative included four phases: (1) Phase I, criteria generation by surveys and literature review; (2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; (3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and (4) Phase IV, validation using independent adjudicators’ consensus as the gold standard. Results. The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion, followed by additive weighted criteria (score range 1–7 points each) clustered into six clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and two laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti–β 2 -glycoprotein I antibodies). Patients accumulating at least three points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria vs the 2006 revised Sapporo classification criteria had a specificity of 99% vs 86%, and a sensitivity of 84% vs 99%. Conclusion. These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.

Dates et versions

hal-04583619 , version 1 (22-05-2024)

Identifiants

Citer

Medha Barbhaiya, Stephane Zuily, Ray Naden, Alison Hendry, Florian Manneville, et al.. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Annals of the Rheumatic Diseases, 2023, 82 (10), pp.1258-1270. ⟨10.1136/ard-2023-224609⟩. ⟨hal-04583619⟩
28 Consultations
0 Téléchargements

Altmetric

Partager

More